{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:54:03Z","timestamp":1791672843587,"version":"4.3.4"},"reference-count":59,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the review were organized to show both benefits or consequences from antiplatelet pharmacotherapy. Conclusively, this review provides a potential synopsis on the most appropriate therapeutic approach for stroke prevention in clinical practice.<\/jats:p>","DOI":"10.3390\/ijerph17165840","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T09:14:49Z","timestamp":1597223689000},"page":"5840","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9264-0061","authenticated-orcid":false,"given":"Salvatore Santo","family":"Signorelli","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"},{"name":"General Medicine Division, University Hospital G. Rodolico, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Platania","sequence":"additional","affiliation":[{"name":"General Medicine Division, University Hospital G. Rodolico, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Davide","family":"Tomasello","sequence":"additional","affiliation":[{"name":"Division of Hemodynamic and Interventional Cardiology, Hospital Cannizzaro, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mangiafico","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Barcellona","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"},{"name":"General Medicine Division, University Hospital G. Rodolico, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4529-3703","authenticated-orcid":false,"given":"Domenico","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Stroke Care, Department of Promoting Health, Maternal-Infant, Excellence and Internal and Specialized Medicine (Promise) G. D\u2019Alessandro, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-9606","authenticated-orcid":false,"given":"Agostino","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"ref_1","first-page":"S241","article-title":"Antiplatelet drugs","volume":"147","author":"Born","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an Antiplatelet Drug","volume":"330","author":"Wood","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/STROKEAHA.113.002590","article-title":"Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases","volume":"45","author":"Gouya","year":"2014","journal-title":"Stroke"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the Early Management of Patients With Acute Ischemic Stroke","volume":"44","author":"Jauch","year":"2013","journal-title":"Stroke"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group (1989). Final Report on the Aspirin Component of the Ongoing Physicians\u2019 Health Study. N. Engl. J. Med., 321, 129\u2013135.","DOI":"10.1056\/NEJM198907203210301"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project","volume":"357","author":"Roncaglioni","year":"2001","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","article-title":"Role of aspirin in primary prevention of cardiovascular disease","volume":"16","author":"Patrono","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/STROKEAHA.112.672451","article-title":"Effect of low-dose aspirin on functional outcome from cerebral vascular events in women","volume":"44","author":"Rist","year":"2013","journal-title":"Stroke"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Investigators Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients with Type 2 Diabetes: A Randomized Controlled Trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older with Atherosclerotic Risk Factors","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/STROKEAHA.115.012461","article-title":"Aspirin for Stroke Prevention in Elderly Patients with Vascular Risk Factors","volume":"47","author":"Uchiyama","year":"2016","journal-title":"Stroke"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"ASCEND Study Collaborative Group (2018). Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N. Engl. J. Med., 379, 1529\u20131539.","DOI":"10.1056\/NEJMoa1804988"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"ref_18","first-page":"555","article-title":"Effect of ASA on Cardiovascular Events and Bleeding in the Healthy Elderly","volume":"36","author":"McNeil","year":"2013","journal-title":"Contemp. Clin. Trials"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14779072.2019.1651199","article-title":"Aspirin for the primary prevention of cardiovascular disease: Latest evidence","volume":"17","author":"Capodanno","year":"2019","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: A meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"Mahmoud","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for Primary Prevention of Cardiovascular Events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/M18-0222","article-title":"Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018","volume":"168","author":"Chamberlain","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a Day) in Patients after a Transient Ischemic Attack or Minor Ischemic Stroke","volume":"325","author":"Algra","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results","volume":"54","author":"Farrell","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjmed.2007.10.002","article-title":"Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis","volume":"121","author":"Berger","year":"2008","journal-title":"Am. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"ref_31","unstructured":"(2019, September 19). CAST: Randomised Placebo-Controlled Trial of Early Aspirin Use in 20,000 Patients with Acute is Chaemic Stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/9186381\/."},{"key":"ref_32","unstructured":"(2019, September 19). Swedish Aspirin Low-Dose Trial (SALT) of 75 mg Aspirin as Secondary Prophylaxis after Cerebrovascular Ischaemic Events. The SALT Collaborative Group, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/1682734\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1055\/s-0039-1693738","article-title":"Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options","volume":"119","author":"Trenk","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_34","unstructured":"(2019, September 19). A Randomised, Blinded, Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) CAPRIE Steering Committee, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/8918275\/."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","article-title":"Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebo-controlled study","volume":"7","author":"Diener","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"ASA and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jash.2007.07.003","article-title":"Antiplatelet therapy for recurrent stroke prevention: Newer perspectives based on (MATCH), (CHARISMA), and (ESPRIT)","volume":"2","author":"Gorelick","year":"2008","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1161\/STROKEAHA.118.020553","article-title":"Efficacy and Safety of Ticagrelor in Relation to Aspirin Use within the Week before Randomization in the SOCRATES Trial","volume":"49","author":"Wong","year":"2018","journal-title":"Stroke"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14656566.2018.1444029","article-title":"A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: Rationale and study design for a randomized controlled trial\u2014PRASTRO-I trial","volume":"19","author":"Nagao","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2019.02.011","article-title":"Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials","volume":"284","author":"Verdoia","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0404.1999.tb00658.x","article-title":"Second European Stroke Prevention Study: Antiplatelet therapy is effective regardless of age","volume":"99","author":"Sivenius","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2174\/1381612033453910","article-title":"Cilostazol as a unique antithrombotic agent","volume":"9","author":"Kambayashi","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/jscd.2000.7216","article-title":"Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh","year":"2000","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_46","unstructured":"(2019, September 19). Cilostazol for Prevention of Secondary Stroke (CSPS 2): An Aspirin-Controlled, Double-Blind, Randomised Non-Inferiority Trial, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/20833591\/."},{"key":"ref_47","unstructured":"(2019, September 19). Meta-Analysis of Cilostazol Versus Aspirin for the Secondary Prevention of Stroke, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK154057."},{"key":"ref_48","unstructured":"(2019, September 19). Clopidogrel Plus Aspirin Versus Aspirin Alone for Reducing Embolisation in Patients with Acute Symptomatic Cerebral or Carotid Artery Stenosis (CLAIR study): A Randomised, Open-Label, Blinded-Endpoint Trial, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/20335070\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","article-title":"Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial","volume":"111","author":"Markus","year":"2005","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.114.014791","article-title":"Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes","volume":"132","author":"Wang","year":"2015","journal-title":"Circulation"},{"key":"ref_53","unstructured":"(2019, September 19). Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1204133."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1742-1241.2001.tb11007.x","article-title":"European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2)","volume":"55","author":"Diener","year":"2001","journal-title":"Int. J. Clin. Pract."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1474-4422(09)70361-8","article-title":"Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): A randomised, open-label, blinded-endpoint trial","volume":"9","author":"Dengler","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/01.STR.0000149621.95215.ea","article-title":"Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials","volume":"36","author":"Bath","year":"2005","journal-title":"Stroke"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2011.09.038","article-title":"Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: A pilot study","volume":"313","author":"Nakamura","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"ref_58","unstructured":"(2019, September 19). Addition of Cilostazol to Aspirin Therapy for Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Patients Undergoing Percutaneous Coronary Intervention: A Randomized, Open-Label Trial, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/26920606\/."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(17)32849-0","article-title":"Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): A randomised, open-label, phase 3 superiority trial","volume":"391","author":"Bath","year":"2018","journal-title":"Lancet"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/16\/5840\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:59:47Z","timestamp":1760176787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/16\/5840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":59,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["ijerph17165840"],"URL":"https:\/\/doi.org\/10.3390\/ijerph17165840","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]}}}